Search

Your search keyword '"Lee, John K."' showing total 154 results
Start Over Author "Lee, John K." Publication Year Range Last 3 years
154 results on '"Lee, John K."'

2. Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation

Author

Mao, Zhiyuan, Nesterenko, Pavlo A, McLaughlin, Jami, Deng, Weixian, Sojo, Giselle Burton, Cheng, Donghui, Noguchi, Miyako, Chour, William, DeLucia, Diana C, Finton, Kathryn A, Qin, Yu, Obusan, Matthew B, Tran, Wendy, Wang, Liang, Bangayan, Nathanael J, Ta, Lisa, Chen, Chia-Chun, Seet, Christopher S, Crooks, Gay M, Phillips, John W, Heath, James R, Strong, Roland K, Lee, John K, Wohlschlegel, James A, and Witte, Owen N

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Vaccine Related, Immunization, Cancer, 2.1 Biological and endogenous factors, Acid Phosphatase, Antigens, Neoplasm, Epitopes, HLA-A Antigens, HLA-A2 Antigen, Humans, Leukocytes, Mononuclear, Neoplasms, Peptides, Receptors, Antigen, T-Cell, T cell receptor, prostate cancer, immunopeptidome, prostatic acid phosphatase, major histocompatibility complexes
Abstract

Tissue-specific antigens can serve as targets for adoptive T cell transfer-based cancer immunotherapy. Recognition of tumor by T cells is mediated by interaction between peptide-major histocompatibility complexes (pMHCs) and T cell receptors (TCRs). Revealing the identity of peptides bound to MHC is critical in discovering cognate TCRs and predicting potential toxicity. We performed multimodal immunopeptidomic analyses for human prostatic acid phosphatase (PAP), a well-recognized tissue antigen. Three physical methods, including mild acid elution, coimmunoprecipitation, and secreted MHC precipitation, were used to capture a thorough signature of PAP on HLA-A*02:01. Eleven PAP peptides that are potentially A*02:01-restricted were identified, including five predicted strong binders by NetMHCpan 4.0. Peripheral blood mononuclear cells (PBMCs) from more than 20 healthy donors were screened with the PAP peptides. Seven cognate TCRs were isolated which can recognize three distinct epitopes when expressed in PBMCs. One TCR shows reactivity toward cell lines expressing both full-length PAP and HLA-A*02:01. Our results show that a combined multimodal immunopeptidomic approach is productive in revealing target peptides and defining the cloned TCR sequences reactive with prostatic acid phosphatase epitopes.

Published
2022

3. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting

Author

Lee, Eric Hee Jun, Murad, John P., Christian, Lea, Gibson, Jackson, Yamaguchi, Yukiko, Cullen, Cody, Gumber, Diana, Park, Anthony K., Young, Cari, Monroy, Isabel, Yang, Jason, Stern, Lawrence A., Adkins, Lauren N., Dhapola, Gaurav, Gittins, Brenna, Chang, Wen-Chung, Martinez, Catalina, Woo, Yanghee, Cristea, Mihaela, Rodriguez-Rodriguez, Lorna, Ishihara, Jun, Lee, John K., Forman, Stephen J., Wang, Leo D., and Priceman, Saul J.

Published
2023
Full Text
View/download PDF

4. Large libraries of single-chain trimer peptide-MHCs enable antigen-specific CD8+ T cell discovery and analysis

Author

Chour, William, Choi, Jongchan, Xie, Jingyi, Chaffee, Mary E., Schmitt, Thomas M., Finton, Kathryn, DeLucia, Diana C., Xu, Alexander M., Su, Yapeng, Chen, Daniel G., Zhang, Rongyu, Yuan, Dan, Hong, Sunga, Ng, Alphonsus H. C., Butler, Jonah Z., Edmark, Rick A., Jones, Lesley C., Murray, Kim M., Peng, Songming, Li, Guideng, Strong, Roland K., Lee, John K., Goldman, Jason D., Greenberg, Philip D., and Heath, James R.

Published
2023
Full Text
View/download PDF

5. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy

Author

Bhatia, Vipul, Kamat, Nikhil V., Pariva, Tiffany E., Wu, Li-Ting, Tsao, Annabelle, Sasaki, Koichi, Sun, Huiyun, Javier, Gerardo, Nutt, Sam, Coleman, Ilsa, Hitchcock, Lauren, Zhang, Ailin, Rudoy, Dmytro, Gulati, Roman, Patel, Radhika A., Roudier, Martine P., True, Lawrence D., Srivastava, Shivani, Morrissey, Colm M., Haffner, Michael C., Nelson, Peter S., Priceman, Saul J., Ishihara, Jun, and Lee, John K.

Published
2023
Full Text
View/download PDF

6. Epileptogenesis in Common Parasitic Infections

Author

Mazumder, Rajarshi and Lee, John K

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Epilepsy, Malaria, Infectious Diseases, Rare Diseases, Neurodegenerative, Brain Disorders, Neurosciences, Vector-Borne Diseases, Aetiology, 2.2 Factors relating to the physical environment, 2.1 Biological and endogenous factors, Infection, Neurological, Good Health and Well Being, Humans, Intestinal Volvulus, Neurocysticercosis, Parasitic Diseases, Reproducibility of Results, Epileptogenesis, Onchocerciasis, Acquired epilepsy, Neurology & Neurosurgery, Biological psychology
Abstract

Purpose of the reviewNeurocysticercosis (NCC) has been well recognized as a leading cause of epilepsy. More recently, studies of other parasitic diseases such as cerebral malaria (CM) and onchocerciasis are yielding novel insights into the pathogenesis of parasite-associated epilepsy. We compare the clinical and electrophysiological findings in epilepsy associated with these highly prevalent parasites and discuss the mechanisms involved in epileptogenesis.Recent findingsElectrophysiological and imaging biomarkers continue to emerge, and individuals who are at-risk of developing parasite-associated epilepsies are being identified with greater reliability. While both Taenia solium and Plasmodium falciparum directly affect the brain parenchyma, Onchocerca volvulus is not known to invade the central nervous system. Thus, the causal association between O. volvulus and epilepsy remains controversial. Both NCC and CM have a well-defined acute phase when the parasites directly or indirectly invade the brain parenchyma and lead to local inflammatory changes. This is followed by a chronic phase marked by recurrent seizures. However, these stages of epileptogenic process have not been identified in the case of O. volvulus.

Published
2022

10. Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression

Author

Jana, Sujata, Brahma, Sandipan, Arora, Sonali, Wladyka, Cynthia L., Hoang, Patrick, Blinka, Steven, Hough, Rowan, Horn, Jessie L., Liu, Yuzhen, Wang, Li-Jie, Depeille, Philippe, Smith, Eric, Montgomery, Robert B., Lee, John K., Haffner, Michael C., Vakar-Lopez, Funda, Grivas, Petros, Wright, Jonathan L., Lam, Hung-Ming, Black, Peter C., Roose, Jeroen P., Ryazanov, Alexey G., Subramaniam, Arvind R., Henikoff, Steven, and Hsieh, Andrew C.

Published
2023
Full Text
View/download PDF

13. Genomic Characterization of Prostatic Basal Cell Carcinoma

Author

Low, Jin-Yih, Ko, Minjeong, Hanratty, Brian, Patel, Radhika A., Bhamidipati, Akshay, Heaphy, Christopher M., Sayar, Erolcan, Lee, John K., Li, Shan, De Marzo, Angelo M., Nelson, William G., Gupta, Anuj, Yegnasubramanian, Srinivasan, Ha, Gavin, Epstein, Jonathan I., and Haffner, Michael C.

Published
2023
Full Text
View/download PDF

14. Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models

Author

Agarwal, Supreet, Fang, Lei, McGowen, Kerry, Yin, JuanJuan, Bowman, Joel, Ku, Anson T., Alilin, Aian Neil, Corey, Eva, Roudier, Martine P., True, Lawrence D., Dumpit, Ruth, Coleman, Ilsa, Lee, John K., Nelson, Peter S., Capaldo, Brian J., Mariani, Aida, Hoover, Clare, Senatorov, Ilya S., Beshiri, Michael, Sowalsky, Adam G., Hurt, Elaine M., and Kelly, Kathleen

Subjects
United States. National Cancer Institute -- Analysis, AstraZeneca PLC, Biopharmaceutics -- Health aspects -- Analysis, Tumor proteins -- Drug therapy, Prostate cancer -- Drug therapy, Antineoplastic agents -- Health aspects -- Analysis, Metastasis -- Drug therapy, Viral antibodies -- Health aspects -- Analysis, Antigens -- Analysis -- Health aspects, Antibodies -- Health aspects -- Analysis, Biological markers -- Health aspects -- Analysis, Pharmaceutical industry -- Health aspects -- Analysis, Antimitotic agents -- Health aspects -- Analysis, Health care industry
Abstract

Antibody-drug conjugates (ADCs) are a promising targeted cancer therapy; however, patient selection based solely on target antigen expression without consideration for cytotoxic payload vulnerabilities has plateaued clinical benefits. Biomarkers to capture patients who might benefit from specific ADCs have not been systematically determined for any cancer. We present a comprehensive therapeutic and biomarker analysis of a B7H3-ADC with pyrrolobenzodiazepine(PBD) payload in 26 treatment- resistant, metastatic prostate cancer (mPC) models. B7H3 is a tumor-specific surface protein widely expressed in mPC, and PBD is a DNA cross-linking agent. B7H3 expression was necessary but not sufficient for B7H3-PBD-ADC responsiveness. RB1 deficiency and/or replication stress, characteristics of poor prognosis, and conferred sensitivity were associated with complete tumor regression in both neuroendocrine (NEPC) and androgen receptor positive (ARPC) prostate cancer models, even with low B7H3 levels. Non-ARPC models, which are currently lacking efficacious treatment, demonstrated the highest replication stress and were most sensitive to treatment. In RB1 WT ARPC tumors, SLFN11 expression or select DNA repair mutations in SLFN11 nonexpressors governed response. Importantly, WT TP53 predicted nonresponsiveness (7 of 8 models). Overall, biomarker-focused selection of models led to high efficacy of in vivo treatment. These data enable a paradigm shift to biomarker-driven trial designs for maximizing clinical benefit of ADC therapies., Introduction Metastatic prostate cancer (mPC) remains a lethal disease accounting for more than 30,000 deaths annually in the United States (1). The use of androgen deprivation therapy (ADT) and androgen [...]

Published
2023
Full Text
View/download PDF

15. Clinical MRI morphological analysis of functional seizures compared to seizure-naïve and psychiatric controls

Author

Kerr, Wesley T., Tatekawa, Hiroyuki, Lee, John K., Karimi, Amir H., Sreenivasan, Siddhika S., O'Neill, Joseph, Smith, Jena M., Hickman, L. Brian, Savic, Ivanka, Nasrullah, Nilab, Espinoza, Randall, Narr, Katherine, Salamon, Noriko, Beimer, Nicholas J., Hadjiiski, Lubomir M., Eliashiv, Dawn S., Stacey, William C., Engel, Jerome, Jr., Feusner, Jamie D., and Stern, John M.

Published
2022
Full Text
View/download PDF

16. MP35-18 AGREEMENT BETWEEN TRANSURETHRAL RESECTION OF BLADDER TUMOR (TURBT) AND RADICAL CYSTECTOMY (RC) PATHOLOGY IN PATIENTS WITH BLADDER CANCER SUBTYPE HISTOLOGY

Author

Bakaloudi, Dimitra Rafailia, primary, Koehne, Elizabeth L., additional, Makrakis, Dimitrios, additional, Diamandopoulos, Leonidas N., additional, Grivas, Petros, additional, Winters, Brian R., additional, True, Lawrence D., additional, Tretiakova, Maria S., additional, Psutka, Sarah P., additional, Holt, Sarah K., additional, John, Gore L., additional, Lin, Daniel W., additional, Schade, George R., additional, Nyame, Yaw, additional, Hsieh, Andrew C., additional, Lee, John K., additional, Yezefski, Todd, additional, Hawley, Jessica, additional, Schweizer, Michael T., additional, Cheng, Heather H., additional, Yu, Evan Y., additional, Vakar-Lopez, Funda, additional, Montgomery, Bruce R., additional, and Wright, Jonathan, additional

Published
2024
Full Text
View/download PDF

19. Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy

Author

Sekar, Rishi R., Diamantopoulos, Leonidas N., Bakaloudi, Dimitra R., Khaki, Ali R., Grivas, Petros, Winters, Brian R., Vakar-Lopez, Funda, Tretiakova, Maria S., Psutka, Sarah P., Holt, Sarah K., Gore, John L., Lin, Daniel W., Schade, George R., Hsieh, Andrew C., Lee, John K., Yezefski, Todd, Schweizer, Michael T., Cheng, Heather H., Yu, Evan Y., True, Lawrence D., Montgomery, R. Bruce., and Wright, Jonathan L.

Published
2023
Full Text
View/download PDF

20. Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer

Author

Vichas, Athea, Riley, Amanda K., Nkinsi, Naomi T., Kamlapurkar, Shriya, Parrish, Phoebe C. R., Lo, April, Duke, Fujiko, Chen, Jennifer, Fung, Iris, Watson, Jacqueline, Rees, Matthew, Gabel, Austin M., Thomas, James D., Bradley, Robert K., Lee, John K., Hatch, Emily M., Baine, Marina K., Rekhtman, Natasha, Ladanyi, Marc, Piccioni, Federica, and Berger, Alice H.

Published
2021
Full Text
View/download PDF

22. Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates.

Author

Ajkunic, Azra, Sayar, Erolcan, Roudier, Martine P., Patel, Radhika A., Coleman, Ilsa M., De Sarkar, Navonil, Hanratty, Brian, Adil, Mohamed, Zhao, Jimmy, Zaidi, Samir, True, Lawrence D., Sperger, Jamie M., Cheng, Heather H., Yu, Evan Y., Montgomery, Robert B., Hawley, Jessica E., Ha, Gavin, Persse, Thomas, Galipeau, Patricia, and Lee, John K.

Subjects
PROSTATE-specific membrane antigen, METASTASIS, CELL adhesion molecules, CASTRATION-resistant prostate cancer, TUMOR proteins
Abstract

Therapeutic approaches targeting proteins on the surface of cancer cells have emerged as an important strategy for precision oncology. To capitalize on the potential impact of drugs targeting surface proteins, detailed knowledge about the expression patterns of the target proteins in tumor tissues is required. In castration-resistant prostate cancer (CRPC), agents targeting prostate-specific membrane antigen (PSMA) have demonstrated clinical activity. However, PSMA expression is lost in a significant number of CRPC tumors. The identification of additional cell surface targets is necessary to develop new therapeutic approaches. Here, we performed a comprehensive analysis of the expression heterogeneity and co-expression patterns of trophoblast cell-surface antigen 2 (TROP2), delta-like ligand 3 (DLL3), and carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) in CRPC samples from a rapid autopsy cohort. We show that DLL3 and CEACAM5 exhibit the highest expression in neuroendocrine prostate cancer (NEPC), while TROP2 is expressed across different CRPC molecular subtypes, except for NEPC. We further demonstrated that AR alterations were associated with higher expression of PSMA and TROP2. Conversely, PSMA and TROP2 expression was lower in RB1-altered tumors. In addition to genomic alterations, we show a tight correlation between epigenetic states, particularly histone H3 lysine 27 methylation (H3K27me3) at the transcriptional start site and gene body of TACSTD2 (encoding TROP2), DLL3, and CEACAM5, and their respective protein expression in CRPC patient-derived xenografts. Collectively, these findings provide insights into patterns and determinants of expression of TROP2, DLL3, and CEACAM5 with implications for the clinical development of cell surface targeting agents in CRPC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Supplementary Figure 14 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers

Author

Zhang, Ailin, primary, Lau, Nathan A., primary, Wong, Alicia, primary, Brown, Lisha G., primary, Coleman, Ilsa M., primary, De Sarkar, Navonil, primary, Li, Dapei, primary, DeLucia, Diana C., primary, Labrecque, Mark P., primary, Nguyen, Holly M., primary, Conner, Jennifer L., primary, Dumpit, Ruth F., primary, True, Lawrence D., primary, Lin, Daniel W., primary, Corey, Eva, primary, Alumkal, Joshi J., primary, Nelson, Peter S., primary, Morrissey, Colm, primary, and Lee, John K., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 8 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers

Author

Zhang, Ailin, primary, Lau, Nathan A., primary, Wong, Alicia, primary, Brown, Lisha G., primary, Coleman, Ilsa M., primary, De Sarkar, Navonil, primary, Li, Dapei, primary, DeLucia, Diana C., primary, Labrecque, Mark P., primary, Nguyen, Holly M., primary, Conner, Jennifer L., primary, Dumpit, Ruth F., primary, True, Lawrence D., primary, Lin, Daniel W., primary, Corey, Eva, primary, Alumkal, Joshi J., primary, Nelson, Peter S., primary, Morrissey, Colm, primary, and Lee, John K., primary

Published
2023
Full Text
View/download PDF

25. Data from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers

Author

Zhang, Ailin, primary, Lau, Nathan A., primary, Wong, Alicia, primary, Brown, Lisha G., primary, Coleman, Ilsa M., primary, De Sarkar, Navonil, primary, Li, Dapei, primary, DeLucia, Diana C., primary, Labrecque, Mark P., primary, Nguyen, Holly M., primary, Conner, Jennifer L., primary, Dumpit, Ruth F., primary, True, Lawrence D., primary, Lin, Daniel W., primary, Corey, Eva, primary, Alumkal, Joshi J., primary, Nelson, Peter S., primary, Morrissey, Colm, primary, and Lee, John K., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table 3 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers

Author

Zhang, Ailin, primary, Lau, Nathan A., primary, Wong, Alicia, primary, Brown, Lisha G., primary, Coleman, Ilsa M., primary, De Sarkar, Navonil, primary, Li, Dapei, primary, DeLucia, Diana C., primary, Labrecque, Mark P., primary, Nguyen, Holly M., primary, Conner, Jennifer L., primary, Dumpit, Ruth F., primary, True, Lawrence D., primary, Lin, Daniel W., primary, Corey, Eva, primary, Alumkal, Joshi J., primary, Nelson, Peter S., primary, Morrissey, Colm, primary, and Lee, John K., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 5 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers

Author

Zhang, Ailin, primary, Lau, Nathan A., primary, Wong, Alicia, primary, Brown, Lisha G., primary, Coleman, Ilsa M., primary, De Sarkar, Navonil, primary, Li, Dapei, primary, DeLucia, Diana C., primary, Labrecque, Mark P., primary, Nguyen, Holly M., primary, Conner, Jennifer L., primary, Dumpit, Ruth F., primary, True, Lawrence D., primary, Lin, Daniel W., primary, Corey, Eva, primary, Alumkal, Joshi J., primary, Nelson, Peter S., primary, Morrissey, Colm, primary, and Lee, John K., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 3 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers

Author

Zhang, Ailin, primary, Lau, Nathan A., primary, Wong, Alicia, primary, Brown, Lisha G., primary, Coleman, Ilsa M., primary, De Sarkar, Navonil, primary, Li, Dapei, primary, DeLucia, Diana C., primary, Labrecque, Mark P., primary, Nguyen, Holly M., primary, Conner, Jennifer L., primary, Dumpit, Ruth F., primary, True, Lawrence D., primary, Lin, Daniel W., primary, Corey, Eva, primary, Alumkal, Joshi J., primary, Nelson, Peter S., primary, Morrissey, Colm, primary, and Lee, John K., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 6 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers

Author

Zhang, Ailin, primary, Lau, Nathan A., primary, Wong, Alicia, primary, Brown, Lisha G., primary, Coleman, Ilsa M., primary, De Sarkar, Navonil, primary, Li, Dapei, primary, DeLucia, Diana C., primary, Labrecque, Mark P., primary, Nguyen, Holly M., primary, Conner, Jennifer L., primary, Dumpit, Ruth F., primary, True, Lawrence D., primary, Lin, Daniel W., primary, Corey, Eva, primary, Alumkal, Joshi J., primary, Nelson, Peter S., primary, Morrissey, Colm, primary, and Lee, John K., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table 1 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers

Author

Zhang, Ailin, primary, Lau, Nathan A., primary, Wong, Alicia, primary, Brown, Lisha G., primary, Coleman, Ilsa M., primary, De Sarkar, Navonil, primary, Li, Dapei, primary, DeLucia, Diana C., primary, Labrecque, Mark P., primary, Nguyen, Holly M., primary, Conner, Jennifer L., primary, Dumpit, Ruth F., primary, True, Lawrence D., primary, Lin, Daniel W., primary, Corey, Eva, primary, Alumkal, Joshi J., primary, Nelson, Peter S., primary, Morrissey, Colm, primary, and Lee, John K., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure 7 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers

Author

Zhang, Ailin, primary, Lau, Nathan A., primary, Wong, Alicia, primary, Brown, Lisha G., primary, Coleman, Ilsa M., primary, De Sarkar, Navonil, primary, Li, Dapei, primary, DeLucia, Diana C., primary, Labrecque, Mark P., primary, Nguyen, Holly M., primary, Conner, Jennifer L., primary, Dumpit, Ruth F., primary, True, Lawrence D., primary, Lin, Daniel W., primary, Corey, Eva, primary, Alumkal, Joshi J., primary, Nelson, Peter S., primary, Morrissey, Colm, primary, and Lee, John K., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 9 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers

Author

Zhang, Ailin, primary, Lau, Nathan A., primary, Wong, Alicia, primary, Brown, Lisha G., primary, Coleman, Ilsa M., primary, De Sarkar, Navonil, primary, Li, Dapei, primary, DeLucia, Diana C., primary, Labrecque, Mark P., primary, Nguyen, Holly M., primary, Conner, Jennifer L., primary, Dumpit, Ruth F., primary, True, Lawrence D., primary, Lin, Daniel W., primary, Corey, Eva, primary, Alumkal, Joshi J., primary, Nelson, Peter S., primary, Morrissey, Colm, primary, and Lee, John K., primary

Published
2023
Full Text
View/download PDF

33. Concurrent targeting of HDAC and PI3K to overcome phenotypic heterogeneity of castration-resistant and neuroendocrine prostate cancers

Author

Zhang, Ailin, primary, Lau, Nathan A, additional, Wong, Alicia, additional, Brown, Lisha G, additional, Coleman, Ilsa M., additional, De Sarkar, Navonil, additional, Li, Dapei, additional, DeLucia, Diana C, additional, Labrecque, Mark P., additional, Nguyen, Holly M, additional, Conner, Jennifer L, additional, Dumpit, Ruth F, additional, True, Lawrence D., additional, Lin, Daniel W, additional, Corey, Eva, additional, Alumkal, Joshi J., additional, Nelson, Peter S., additional, Morrissey, Colm, additional, and Lee, John K, additional

Published
2023
Full Text
View/download PDF

34. Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancer

Author

Labrecque, Mark P., primary, Brown, Lisha G., additional, Coleman, Ilsa M., additional, Nguyen, Holly M., additional, Dalrymple, Susan, additional, Brennen, W. Nathaniel, additional, Isaacs, John T., additional, Li, Dapei, additional, Lakely, Bryce, additional, DeLucia, Diana C., additional, Lee, John K., additional, Schweizer, Michael T., additional, Lin, Daniel W., additional, Corey, Eva, additional, Nelson, Peter S., additional, and Morrissey, Colm, additional

Published
2023
Full Text
View/download PDF

35. LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function

Author

Kumaraswamy, Anbarasu, primary, Duan, Zhi, additional, Flores, Diana, additional, Zhang, Chao, additional, Sehrawat, Archana, additional, Hu, Ya-Mei, additional, Swaim, Olivia A., additional, Rodansky, Eva, additional, Storck, William K., additional, Kuleape, Joshua A., additional, Bedi, Karan, additional, Mannan, Rahul, additional, Wang, Xiao-Ming, additional, Udager, Aaron, additional, Ravikumar, Visweswaran, additional, Bankhead, Armand, additional, Coleman, Ilsa, additional, Lee, John K., additional, Morrissey, Colm, additional, Nelson, Peter S., additional, Chinnaiyan, Arul M., additional, Rao, Arvind, additional, Xia, Zheng, additional, Yates, Joel A., additional, and Alumkal, Joshi J., additional

Published
2023
Full Text
View/download PDF

38. Combinatorial genetic strategy accelerates the discovery of cancer genotype-phenotype associations

Author

Li, Shan, primary, Wong, Alicia, additional, Sun, Huiyun, additional, Bhatia, Vipul, additional, Javier, Gerardo, additional, Jana, Sujata, additional, Mongomery, Robert B, additional, Wright, Jonathan L, additional, Lam, Hung-Ming, additional, Hsieh, Andrew C, additional, Faltas, Bishoy M, additional, Haffner, Michael C, additional, and Lee, John K, additional

Published
2023
Full Text
View/download PDF

39. Data from Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations

Author

Patel, Radhika A., primary, Coleman, Ilsa, primary, Roudier, Martine P., primary, Konnick, Eric Q., primary, Hanratty, Brian, primary, Dumpit, Ruth, primary, Lucas, Jared M., primary, Ang, Lisa S., primary, Low, Jin-Yih, primary, Tretiakova, Maria S., primary, Ha, Gavin, primary, Lee, John K., primary, True, Lawrence D., primary, De Marzo, Angelo M., primary, Nelson, Peter S., primary, Morrissey, Colm, primary, Pritchard, Colin C., primary, and Haffner, Michael C., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figures 1-19, Tables 1-2 from Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations

Author

Patel, Radhika A., primary, Coleman, Ilsa, primary, Roudier, Martine P., primary, Konnick, Eric Q., primary, Hanratty, Brian, primary, Dumpit, Ruth, primary, Lucas, Jared M., primary, Ang, Lisa S., primary, Low, Jin-Yih, primary, Tretiakova, Maria S., primary, Ha, Gavin, primary, Lee, John K., primary, True, Lawrence D., primary, De Marzo, Angelo M., primary, Nelson, Peter S., primary, Morrissey, Colm, primary, Pritchard, Colin C., primary, and Haffner, Michael C., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Methods, Supplementary Figures 1-6 from Targeting RET Kinase in Neuroendocrine Prostate Cancer

Author

VanDeusen, Halena R., primary, Ramroop, Johnny R., primary, Morel, Katherine L., primary, Bae, Song Yi, primary, Sheahan, Anjali V., primary, Sychev, Zoi, primary, Lau, Nathan A., primary, Cheng, Larry C., primary, Tan, Victor M., primary, Li, Zhen, primary, Petersen, Ashley, primary, Lee, John K., primary, Park, Jung Wook, primary, Yang, Rendong, primary, Hwang, Justin H., primary, Coleman, Ilsa, primary, Witte, Owen N., primary, Morrissey, Colm, primary, Corey, Eva, primary, Nelson, Peter S., primary, Ellis, Leigh, primary, and Drake, Justin M., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Tables 1-8 from Targeting RET Kinase in Neuroendocrine Prostate Cancer

Author

VanDeusen, Halena R., primary, Ramroop, Johnny R., primary, Morel, Katherine L., primary, Bae, Song Yi, primary, Sheahan, Anjali V., primary, Sychev, Zoi, primary, Lau, Nathan A., primary, Cheng, Larry C., primary, Tan, Victor M., primary, Li, Zhen, primary, Petersen, Ashley, primary, Lee, John K., primary, Park, Jung Wook, primary, Yang, Rendong, primary, Hwang, Justin H., primary, Coleman, Ilsa, primary, Witte, Owen N., primary, Morrissey, Colm, primary, Corey, Eva, primary, Nelson, Peter S., primary, Ellis, Leigh, primary, and Drake, Justin M., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Materials and Methods from RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer

Author

Labrecque, Mark P., primary, Brown, Lisha G., primary, Coleman, Ilsa M., primary, Lakely, Bryce, primary, Brady, Nicholas J., primary, Lee, John K., primary, Nguyen, Holly M., primary, Li, Dapei, primary, Hanratty, Brian, primary, Haffner, Michael C., primary, Rickman, David S., primary, True, Lawrence D., primary, Lin, Daniel W., primary, Lam, Hung-Ming, primary, Alumkal, Joshi J., primary, Corey, Eva, primary, Nelson, Peter S., primary, and Morrissey, Colm, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figures S1-S13 from RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer

Author

Labrecque, Mark P., primary, Brown, Lisha G., primary, Coleman, Ilsa M., primary, Lakely, Bryce, primary, Brady, Nicholas J., primary, Lee, John K., primary, Nguyen, Holly M., primary, Li, Dapei, primary, Hanratty, Brian, primary, Haffner, Michael C., primary, Rickman, David S., primary, True, Lawrence D., primary, Lin, Daniel W., primary, Lam, Hung-Ming, primary, Alumkal, Joshi J., primary, Corey, Eva, primary, Nelson, Peter S., primary, and Morrissey, Colm, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Tables S1-S12 from RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer

Author

Labrecque, Mark P., primary, Brown, Lisha G., primary, Coleman, Ilsa M., primary, Lakely, Bryce, primary, Brady, Nicholas J., primary, Lee, John K., primary, Nguyen, Holly M., primary, Li, Dapei, primary, Hanratty, Brian, primary, Haffner, Michael C., primary, Rickman, David S., primary, True, Lawrence D., primary, Lin, Daniel W., primary, Lam, Hung-Ming, primary, Alumkal, Joshi J., primary, Corey, Eva, primary, Nelson, Peter S., primary, and Morrissey, Colm, primary

Published
2023
Full Text
View/download PDF

46. Figure S3 from Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer

Author

Corella, Alexandra N., primary, Cabiliza Ordonio, Ma Victoria Andrea, primary, Coleman, Ilsa, primary, Lucas, Jared M., primary, Kaipainen, Arja, primary, Nguyen, Holly M., primary, Sondheim, Daniel, primary, Brown, Lisha G., primary, True, Lawrence D., primary, Lee, John K., primary, MacPherson, David, primary, Nghiem, Paul, primary, Gulati, Roman, primary, Morrissey, Colm, primary, Corey, Eva, primary, and Nelson, Peter S., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Data from Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5–SN38 Antibody–drug Conjugate in Neuroendocrine Prostate Cancer

Author

DeLucia, Diana C., primary, Cardillo, Thomas M., primary, Ang, Lisa, primary, Labrecque, Mark P., primary, Zhang, Ailin, primary, Hopkins, James E., primary, De Sarkar, Navonil, primary, Coleman, Ilsa, primary, da Costa, Rui M. Gil, primary, Corey, Eva, primary, True, Lawrence D., primary, Haffner, Michael C., primary, Schweizer, Michael T., primary, Morrissey, Colm, primary, Nelson, Peter S., primary, and Lee, John K., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Tables 1-4 from Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5–SN38 Antibody–drug Conjugate in Neuroendocrine Prostate Cancer

Author

DeLucia, Diana C., primary, Cardillo, Thomas M., primary, Ang, Lisa, primary, Labrecque, Mark P., primary, Zhang, Ailin, primary, Hopkins, James E., primary, De Sarkar, Navonil, primary, Coleman, Ilsa, primary, da Costa, Rui M. Gil, primary, Corey, Eva, primary, True, Lawrence D., primary, Haffner, Michael C., primary, Schweizer, Michael T., primary, Morrissey, Colm, primary, Nelson, Peter S., primary, and Lee, John K., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results